	US 12,133,914 B2
	Hydrocortisone oral liquid formulations
Danka Radosavljevic, Palatine, IL (US); Sean Brynjelsen, Barrington, IL (US); Romona Bhattacharya, Franklin Park, NJ (US); and Kalyan Kathala, Monroe, NJ (US)
Assigned to Eton Pharmaceuticals, Inc., Deer Park, IL (US)
Filed by Eton Pharmaceuticals, Inc., Deer Park, IL (US)
Filed on Feb. 16, 2024, as Appl. No. 18/443,889.
Application 18/443,889 is a continuation of application No. PCT/US2023/079494, filed on Nov. 13, 2023.
Application PCT/US2023/079494 is a continuation in part of application No. 18/113,458, filed on Feb. 23, 2023, granted, now 11,904,046, issued on Feb. 20, 2024.
Claims priority of provisional application 63/425,172, filed on Nov. 14, 2022.
Prior Publication US 2024/0216270 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/46 (2006.01)

CPC A61K 9/0053 (2013.01) [A61K 9/08 (2013.01); A61K 31/573 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/46 (2013.01)]

20 Claims

1. A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a liquid pharmaceutical composition, wherein the liquid pharmaceutical composition is an oral liquid that comprises:

hydrocortisone or a pharmaceutically acceptable salt thereof; and

a nonaqueous liquid carrier, wherein the nonaqueous liquid carrier is present in the liquid pharmaceutical composition in an amount of from about 70% weight by weight (% wt) to about 99.9% wt;

wherein the liquid pharmaceutical composition contains less than 5% wt of water; and

wherein the disease or condition comprises endocrine disorders.